<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16966</article-id><article-id pub-id-type="doi">10.25208/vdv16966</article-id><article-id pub-id-type="edn">CVGQAK</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL CASE REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>НАБЛЮДЕНИЕ ИЗ ПРАКТИКИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Scleromyxedema as a manifestation of monoclonal gammopathy of clinical significance</article-title><trans-title-group xml:lang="ru"><trans-title>Склеромикседема как проявление моноклональной гаммапатии клинического значения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9688-2727</contrib-id><contrib-id contrib-id-type="spin">3385-4723</contrib-id><name-alternatives><name xml:lang="en"><surname>Chikin</surname><given-names>Vadim V.</given-names></name><name xml:lang="ru"><surname>Чикин</surname><given-names>Вадим Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>chikin@cnikvi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4142-171X</contrib-id><contrib-id contrib-id-type="spin">4469-5909</contrib-id><name-alternatives><name xml:lang="en"><surname>Soloveva</surname><given-names>Maiia V.</given-names></name><name xml:lang="ru"><surname>Соловьёва</surname><given-names>Майя Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Hematologist</p></bio><bio xml:lang="ru"><p>канд. мед. наук, врач-гематолог</p></bio><email>solomaiia@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1082-8659</contrib-id><contrib-id contrib-id-type="spin">3702-8208</contrib-id><name-alternatives><name xml:lang="en"><surname>Kovrigina</surname><given-names>Alla M.</given-names></name><name xml:lang="ru"><surname>Ковригина</surname><given-names>Алла Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>kovrigina-alla@mail.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1141-9352</contrib-id><contrib-id contrib-id-type="spin">1307-1189</contrib-id><name-alternatives><name xml:lang="en"><surname>Nefedova</surname><given-names>Maria A.</given-names></name><name xml:lang="ru"><surname>Нефёдова</surname><given-names>Мария Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>nefedova.maria.arb@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Research Center of Dermatovenereology and Cosmetology</institution></aff><aff><institution xml:lang="ru">Государственный научный центр дерматовенерологии и косметологии</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Medical Research Center of Hematology</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр гематологии</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">The First Sechenov Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-07-17" publication-format="electronic"><day>17</day><month>07</month><year>2026</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-08-27" publication-format="electronic"><day>27</day><month>08</month><year>2026</year></pub-date><volume>102</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>77</fpage><lpage>91</lpage><history><date date-type="received" iso-8601-date="2026-02-26"><day>26</day><month>02</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-06-19"><day>19</day><month>06</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Chikin V.V., Soloveva M.V., Kovrigina A.M., Nefedova M.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Чикин В.В., Соловьёва М.В., Ковригина А.М., Нефёдова М.А.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Chikin V.V., Soloveva M.V., Kovrigina A.M., Nefedova M.A.</copyright-holder><copyright-holder xml:lang="ru">Чикин В.В., Соловьёва М.В., Ковригина А.М., Нефёдова М.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/16966">https://vestnikdv.ru/jour/article/view/16966</self-uri><abstract xml:lang="en"><p>The article describes a 57-year-old female patient with lesions on the scalp, trunk and extremities, who was diagnosed with scleromyxedema (myxedematous lichen) by a dermatovenereologist based on clinical data and histopathological examination of a skin specimen. An immunochemical study of serum proteins revealed an M-gradient in the g3 zone, formed by a Gk clone and amounting to 4.9 g/L. Immunophenotyping of blood cells revealed a population of clonal plasma cells with the CD138<sup>+</sup>CD38<sup>+</sup>CD56<sup>–</sup>CD10<sup>–</sup>CD117–kappa<sup>+</sup> immunophenotype (2.26% of all studied events).</p> <p>Upon further examination by a hematologist, 2% of plasma cells were detected in the myelogram. Immunophenotyping of bone marrow cells by flow cytometry revealed 0.144% of plasma cells from all cells with the aberrant immunophenotype CD38dimCD138<sup>+</sup>CD319<sup>+</sup>CD19<sup>–</sup>CD45<sup>+</sup>/<sup>–</sup>CD56<sup>+</sup>/<sup>–</sup>CD27<sup>+</sup>/<sup>–</sup>CD117<sup>–</sup>/<sup>+</sup>CD200<sup>+</sup>CD20<sup>–</sup>/<sup>+</sup>. No criteria for symptomatic multiple myeloma or smoldering myeloma were found. The patient was diagnosed with monoclonal gammopathy of clinical significance, with predominant generalized skin involvement, associated with a monoclonal IgG secretion. VRD-based therapy (bortezomib, lenalidomide, dexamethasone) followed by autologous hematopoietic stem cell transplantation led to significant improvement. Gk secretion decreased to a trace, the bone marrow was sanitized, and a significant improvement in the patient’s skin condition was noted.</p> <p>The presented case demonstrates the association of scleromyxedema with monoclonal gammopathy and indicates the need for patients with scleromyxedema to be examined by a hematologist.</p></abstract><trans-abstract xml:lang="ru"><p>Описана пациентка 57 лет с поражением кожи головы, туловища и конечностей, у которой на основании клинических данных и гистологического исследования биоптата кожи врачом-дерматовенерологом был установлен диагноз склеромикседемы (микседематозный лихен). При иммунохимическом исследовании белков сыворотки крови у неё был выявлен М-градиент в g3-зоне, образованный клоном G и составивший 4,9 г/л. Проведено иммунофенотипирование клеток крови, в результате обнаружена популяция клональных плазматических клеток с иммунофенотипом CD138<sup>+</sup>CD38<sup>+</sup>CD56<sup>–</sup>CD10<sup>–</sup>CD117-каппа<sup>+</sup> (2,26% всех исследованных событий).</p> <p>При дальнейшем обследовании врачом-гематологом в миелограмме определено 2% плазматических клеток. При иммунофенотипировании клеток костного мозга методом проточной цитометрии выявлено 0,144% плазматических клеток от всех клеток с аберрантным иммунофенотипом CD38dimCD138<sup>+</sup>CD319<sup>+</sup>CD19<sup>–</sup>CD45<sup>+</sup>/<sup>–</sup>CD56<sup>+</sup>/<sup>–</sup>CD27<sup>+</sup>/<sup>–</sup>CD117<sup>–</sup>/<sup>+</sup>CD200<sup>+</sup>CD20<sup>–</sup>/<sup>+</sup>. Критериев симптоматической множественной миеломы, тлеющей миеломы не обнаружено. Пациентке установлен диагноз «моноклональная гаммапатия клинического значения, с преимущественным тотальным поражением кожи, склеромикседемой, протекающая с моноклональной секрецией G». Проведённая терапия по схеме VRD (бортезомиб, леналидомид, дексаметазон) с последующей трансплантацией аутологичных гемопоэтических стволовых клеток позволила достичь значительного улучшения. Секреция G уменьшилась до следовой, костный мозг был санирован, отмечено значительное улучшение состояния кожи пациентки.</p> <p>Представленный случай демонстрирует ассоциацию склеромикседемы с моноклональной гаммапатией и указывает на необходимость обследования пациентов со склеромикседемой врачом-гематологом.</p></trans-abstract><kwd-group xml:lang="en"><kwd>scleromyxedema</kwd><kwd>lichen myxedematosus</kwd><kwd>monoclonal gammopathy</kwd><kwd>paraprotein</kwd><kwd>case report</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>склеромикседема</kwd><kwd>микседематозный лихен</kwd><kwd>моноклональная гаммапатия</kwd><kwd>парапротеин</kwd><kwd>клинический случай</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Daoud MS, Lust JA, Kyle RA, Pittelkow MR. Monoclonal gammopathies and associated skin disorders. J Am Acad Dermatol. 1999;40(4):507–538. doi: 10.1016/s0190-9622(99)70434-2</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Claveau JS, Wetter DA, Kumar S. Cutaneous manifestations of monoclonal gammopathy. Blood Cancer J. 2022;12(4):58. doi: 10.1038/s41408-022-00661-1 EDN: FWXBCS</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bhutani M, Shahid Z, Schnebelen A, et al. Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders. Semin Oncol. 2016;43(3):395–400. doi: 10.1053/j.seminoncol.2016.02.017</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Neufeld M, Sunderkötter C, Moritz RKC. Scleromyxedema. Hautarzt. 2018;69(11):916–921. (In Germany). doi: 10.1007/s00105-018-4257-8 EDN: ZPAQGV</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol. 2013;69(1):66–72. doi: 10.1016/j.jaad.2013.01.007</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Rongioletti F. Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg. 2006;25(2):100–104. doi: 10.1016/j.sder.2006.04.001</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Cokonis Georgakis CD, Falasca G, et al. Scleromyxedema. Clin Dermatol. 2006;24(6):493–497. doi: 10.1016/j.clindermatol.2006.07.011</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Haber R, Bachour J, El Gemayel M. Scleromyxedema treatment: a systematic review and update. Int J Dermatol. 2020;59(10):1191–1201. doi: 10.1111/ijd.14888 EDN: GFZMTC</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Webster GF, Matsuoka LY, Burchmore D. The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol. 1993;28(1):105–108. doi: 10.1016/0190-9622(93)70021-k</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Godby A, Bergstresser PR, Chaker B, Pandya AG. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol. 1998;38(2 Pt 2):289–294. doi: 10.1016/s0190-9622(98)70567-5</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hummers LK. Scleromyxedema. Curr Opin Rheumatol. 2014;26(6):658–662. doi: 10.1097/BOR.0000000000000118</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44(2):273–281. doi: 10.1067/mjd.2001.111630</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Hoffmann JHO, Enk AH. Scleromyxedema. J Dtsch Dermatol Ges. 2020;18(12):1449–1467. doi: 10.1111/ddg.14319</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Rapp MF, Guram M, Konrad HR, et al. Laryngeal involvement in scleromyxedema: a case report. Otolaryngol Head Neck Surg. 1991;104(3):362–365. doi: 10.1177/019459989110400312</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Hardie RA, Hunter JA, Urbaniak S, Habeshaw JA. Spontaneous resolution of lichen myxoedematosus. Br J Dermatol. 1979;100(6):727–730. doi: 10.1111/j.1365-2133.1979.tb08080.x</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Rongioletti F, Merlo G, Carli C, et al. Histopathologic characteristics of scleromyxedema: A study of a series of 34 cases. J Am Acad Dermatol. 2016;74(6):1194–1200. doi: 10.1016/j.jaad.2015.12.021</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87(1):10–20. doi: 10.1097/MD.0b013e3181630835</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Fleming KE, Virmani D, Sutton E, et al. Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature. J Cutan Pathol. 2012;39(5):508–517. doi: 10.1111/j.1600-0560.2012.01882.x</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol. 2003;42(1):31–35. doi: 10.1046/j.1365-4362.2003.01565.x EDN: BEXBZZ</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Helfrich DJ, Walker ER, Martinez AJ, Medsger TA Jr. Scleromyxedema myopathy: case report and review of the literature. Arthritis Rheum. 1988;31(11):1437–1441. doi: 10.1002/art.1780311115</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33(1):37–43. doi: 10.1016/0190-9622(95)90007-1</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Rothe MJ, Rivas R, Gould E, Kerdel FA. Scleromyxedema and severe myositis. 1989;28(10):657–660. doi: 10.1111/j.1365-4362.1989.tb02436.x</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Lee YH, Sahu J, O’Brien MS, et al. Scleroderma renal crisis-like acute renal failure associated with mucopolysaccharide accumulation in renal vessels in a patient with scleromyxedema. J Clin Rheumatol. 2011;17(6):318–322. doi: 10.1097/RHU.0b013e31822be61e</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Starovoitova MN, Desinova OV, Guseva NG. Scleromyxedema concurrent with dermatomyositis and paraproteinemia: A case report. Modern Rheumatology Journal. 2015;(1):44. doi: 10.14412/1996-7012-2015-1-44-47 EDN: TLJURX</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Chan JC, Trendell-Smith NJ, Yeung CK. Scleromyxedema: a cutaneous paraneoplastic syndrome associated with thymic carcinoma. J Clin Oncol. 2012;30(3):e27–e29. doi: 10.1200/JCO.2011.38.3935</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Wick MR, Patterson JW. Cutaneous paraneoplastic syndromes. Semin Diagn Pathol. 2019;36(4):211–228. doi: 10.1053/j.semdp.2019.01.001</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Clark BJ, Mowat A, Fallowfield ME, Lee FD. Papular mucinosis: is the inflammatory cell infiltrate neoplastic? The presence of a monotypic plasma cell population demonstrated by in situ hybridization. British Journal of Dermatology. 1996;135(3):467–470. doi: 10.1046/j.1365-2133.1996.d01-1024.x</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Nofal A, Amer H, Alakad R, et al. Lichen myxedematosus: diagnostic criteria, classification, and severity grading. Int J Dermatol. 2017;56(3):284–290. doi: 10.1111/ijd.13437</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241–249. doi: 10.1056/NEJMoa1709974</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Lyubimova NV, Timofeev YS, Votyakova OM, Kushlinskii NE. Free light chains of immunoglobulins in the diagnosis and prognosis of multiple myeloma. Almanac of Clinical Medicine. 2017;45(2):102–108. doi: 10.18786/2072-0505-2017-45-2-102-108 EDN: ZMJLZR</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–1127. doi: 10.1038/leu.2010.60</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Katzmann JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev. 2009;30(3):105–111.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10–45. doi: 10.3322/caac.21871 EDN: MHQXTB</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin Lymphoma Myeloma Leuk. 2015;15(3):177–186.e4. doi: 10.1016/j.clml.2014.09.004</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Smirnov AV, Afanasyev BV, Poddubnaya IV, et al. Monoclonal gammopathy of renal signifi cance: Consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specific treatment. Nephrology (Saint-Petersburg). 2019;23(6):9–28. doi: 10.36485/1561-6274-2019-236-9-28 EDN: VNIKSV</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Cho H. Diagnosis and management of monoclonal gammopathy of clinical significance. Blood Res. 2022;57(S1):20–26. doi: 10.5045/br.2022.2022035 EDN: CIDUTF</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant concept. J Eur Acad Dermatol Venereol. 2017;31(1):45–52. doi: 10.1111/jdv.13847</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Baxi KD, Chaudhary RG, Rathod SP, Jagati A. Monoclonal gammopathy of undetermined significance-associated scleromyxoedema. Indian Dermatol Online J. 2019;10(1):54–57. doi: 10.4103/idoj.IDOJ_138_18</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Pambor M, Lessel W, Quednow C. Malignant non-Hodgkin lymphoma in the clinical course of Arndt–Gottron scleromyxedema. Dermatol Monatsschr. 1983;169(3):171–178.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Giménez Garcia R, Garcia SG, Suarez Vilela D, Moro Sanchez MJ. Scleromyxedema associated with non-Hodgkin lymphoma. Int J Dermatol. 1989;28(10):670–671. doi: 10.1111/j.1365-4362.1989.tb02439.x</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Le Moigne M, Mazereeuw-Hautier J, Bonnetblanc JM, et al. Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study. Ann Dermatol Venereol. 2010;137(12):782–788. doi: 10.1016/j.annder.2010.08.011</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Fett NM, Toporcer MB, Dalmau J, et al. Scleromyxedema and dermato-neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol. 2011;86(10):893–896. doi: 10.1002/ajh.22131</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Victor V, Margareat RM. Plasma cell myeloma masquerading as scleromyxedema. Indian Dermatol Online J. 2019;10(1):50–53. doi: 10.4103/idoj.IDOJ_135_18</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Kreidy M, Al-Hilli A, Yachoui R, Resnick J. Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report. BMC Pulm Med. 2020;20(1):8. doi: 10.1186/s12890-019-1020-6 EDN: JQDATO</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Rayson D, Lust JA, Duncan A, Su WP. Scleromyxedema: a complete response to prednisone. Mayo Clin Proc. 1999;74(5):481–484. doi: 10.4065/74.5.481</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Lin YC, Wang HC, Shen JL. Scleromyxedema: An experience using treatment with systemic corticosteroid and review of the published work. J Dermatol. 2006;33(3):207–210. doi: 10.1111/j.1346-8138.2006.00047.x</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Horn KB, Horn MA, Swan J, et al. A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol. 2004;51(2 Suppl.):S120–S123. doi: 10.1016/j.jaad.2004.03.023</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Kreuter A, Altmeyer P. High-dose dexamethasone in scleromyxedema: report of 2 additional cases. J Am Acad Dermatol. 2005;53(4):739–740. doi: 10.1016/j.jaad.2005.04.012</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Spagnolo F, Nozzoli C, Rini A, et al. Neurological involvement in the course of scleromyxedema: a case report. J Stroke Cerebrovasc Dis. 2016;25(9):e148–e150. doi: 10.1016/j.jstrokecerebrovasdis.2016.05.017</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Xu XL, Wu Q, Zeng XS, Sun JF. Combination of betamethasone and methotrexate for the treatment of scleromyxoedema without paraproteinaemia. Eur J Dermatol. 2016;26(4):391–393. doi: 10.1684/ejd.2016.2794</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Keong CH, Asaka Y, Fukuro S, et al. Successful treatment of scleromyxedema with plasmapheresis and immunosuppression. J Am Acad Dermatol. 1990;22(5 Pt 1):842–844. doi: 10.1016/s0190-9622(08)81176-0</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Lvov AN, Sheklakova MN, Matushevskaya YuI, et al. Arndt–Gottron scleromyxedema. Vestn Dermatol Venerol. 2012;(5):71–77. EDN: PMQGCN</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Drobinina AP, Grachev AE, Ryzhko VV, Gribanova EO. Monoclonal gammopathy of clinical significance (MGCS) with cutaneous involvement. Russian Journal of Hematology and Transfusiology (Gematologiya I Transfusiologiya). 2024;69 (2S1):211. EDN: CYHXMQ</mixed-citation></ref></ref-list></back></article>
